UBS Group AG Boosts Position in ImmunityBio, Inc. $IBRX

UBS Group AG boosted its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 18.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,995,607 shares of the company’s stock after buying an additional 315,025 shares during the period. UBS Group AG’s holdings in ImmunityBio were worth $3,951,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Sanctuary Advisors LLC raised its holdings in ImmunityBio by 6.9% in the fourth quarter. Sanctuary Advisors LLC now owns 29,547 shares of the company’s stock valued at $59,000 after buying an additional 1,918 shares during the period. Bell & Brown Wealth Advisors LLC raised its holdings in ImmunityBio by 6.4% in the third quarter. Bell & Brown Wealth Advisors LLC now owns 82,750 shares of the company’s stock valued at $204,000 after buying an additional 5,000 shares during the period. Creative Planning raised its holdings in ImmunityBio by 9.2% in the second quarter. Creative Planning now owns 62,028 shares of the company’s stock valued at $164,000 after buying an additional 5,231 shares during the period. Courier Capital LLC raised its stake in shares of ImmunityBio by 12.0% during the fourth quarter. Courier Capital LLC now owns 56,000 shares of the company’s stock valued at $111,000 after purchasing an additional 6,000 shares during the period. Finally, Cetera Investment Advisers raised its stake in shares of ImmunityBio by 56.9% during the second quarter. Cetera Investment Advisers now owns 18,551 shares of the company’s stock valued at $49,000 after purchasing an additional 6,731 shares during the period. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on IBRX. BTIG Research reiterated a “buy” rating and set a $12.00 price objective on shares of ImmunityBio in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, April 14th. The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. D. Boral Capital restated a “buy” rating and issued a $23.00 price target on shares of ImmunityBio in a research note on Tuesday, May 5th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of ImmunityBio in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, ImmunityBio currently has a consensus rating of “Moderate Buy” and an average target price of $14.20.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio said a health economic analysis presented at ISPOR 2026 showed ANKTIVA plus BCG delivered a lower cost per sustained complete responder than TAR-200 in BCG-unresponsive NMIBC CIS, a potentially supportive commercial and reimbursement datapoint. Article Title
• Neutral Sentiment: Several broker and research notes remained constructive, including reports of buy ratings from BTIG Research and HC Wainwright, which may help offset some of the negative sentiment around the stock. Article Title
• Neutral Sentiment: News also noted that Anktiva label expansion is undergoing FDA review, which could be a future catalyst if approved, but it remains uncertain for now. Article Title
• Negative Sentiment: A large cluster of law-firm notices and deadline reminders emphasized the May 26 lead-plaintiff deadline in an existing securities class action, reinforcing investor focus on alleged disclosures around ImmunityBio’s Anktiva claims. Article Title
• Negative Sentiment: The lawsuit background centers on an FDA warning letter that allegedly challenged unsupported efficacy claims, a headline that has weighed on sentiment and triggered broader legal scrutiny. Article Title

ImmunityBio Price Performance

ImmunityBio stock opened at $7.22 on Friday. The company has a market cap of $7.56 billion, a PE ratio of -8.49 and a beta of 0.02. The company has a fifty day moving average price of $7.75 and a two-hundred day moving average price of $5.58. ImmunityBio, Inc. has a 12 month low of $1.95 and a 12 month high of $12.43.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.54). The business had revenue of $44.21 million for the quarter, compared to analysts’ expectations of $43.07 million. Equities research analysts anticipate that ImmunityBio, Inc. will post -0.31 earnings per share for the current year.

Insiders Place Their Bets

In other ImmunityBio news, Director Barry J. Simon sold 165,000 shares of ImmunityBio stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. The trade was a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 265,000 shares of company stock valued at $2,842,000. 69.48% of the stock is currently owned by corporate insiders.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.